Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIANA: Tisagenlecleucel in Pediatric r/r B-cell ALL
NCT02435849Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- Jan 2020
- Modality
- CAR-T Cells
- Countries
- 11
01
Overview
A Phase 2 trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Novartis. Started Apr 2015; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02435849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02435849.